ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone Replacement Therapy in Men with History of Prostate Cancer Found Safe
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 5204" data-attributes="member: 3"><p>[ATTACH]516[/ATTACH]</p><p></p><p>Introduction</p><p></p><p>Late-onset hypogonadism may impair quality of life and contribute to metabolic and cardiovascular comorbidity in aging men. Testosterone replacement therapy is effective in treating hypogonadism. However, for the millions of men with a history of prostate cancer, exogenous testosterone has long been considered contraindicated, even though little data in such men are available. Clarification of this safety issue could allow treatment to be considered for a sizeable segment of the aging male population.</p><p></p><p></p><p>Aim The aim of this study is to examine population-based utilization and impact of testosterone replacement therapy in men with prostate cancer.</p><p></p><p></p><p>Methods Using linked Surveillance, Epidemiology, and End Results-Medicare data, <strong>we identified 149,354 men diagnosed with prostate cancer from 1992 to 2007. Of those, 1,181 (0.79%) men received exogenous testosterone following their cancer diagnosis. </strong>We used propensity scoring analysis to examine the effect of testosterone replacement on the use of salvage hormone therapy and overall and prostate cancer-specific mortality.</p><p></p><p></p><p>Main Outcome Measures We assessed overall mortality, cancer-specific mortality, and the use of salvage hormone therapy.</p><p></p><p></p><p>Results Following prostate cancer diagnosis, testosterone replacement was directly related to income and educational status and inversely related to age (all P&#8201;<&#8201;0.001). Men undergoing radical prostatectomy and men with well-differentiated tumors were more likely to receive testosterone (all P&#8201;<&#8201;0.001). On adjusted analysis, testosterone replacement therapy was not associated with overall or cancer-specific mortality or with the use of salvage hormone therapy.</p><p></p><p></p><p><strong>Conclusions In this population-based observational study of testosterone replacement therapy in men with a history of prostate cancer, treatment was not associated with increased overall or cancer-specific mortality. These findings suggest testosterone replacement therapy may be considered in men with a history of prostate cancer, but confirmatory prospective studies are needed.</strong></p><p></p><p><strong><a href="http://onlinelibrary.wiley.com/doi/10.1111/jsm.12429/abstract" target="_blank">Source</a></strong></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 5204, member: 3"] [ATTACH]516[/ATTACH] Introduction Late-onset hypogonadism may impair quality of life and contribute to metabolic and cardiovascular comorbidity in aging men. Testosterone replacement therapy is effective in treating hypogonadism. However, for the millions of men with a history of prostate cancer, exogenous testosterone has long been considered contraindicated, even though little data in such men are available. Clarification of this safety issue could allow treatment to be considered for a sizeable segment of the aging male population. Aim The aim of this study is to examine population-based utilization and impact of testosterone replacement therapy in men with prostate cancer. Methods Using linked Surveillance, Epidemiology, and End Results-Medicare data, [B]we identified 149,354 men diagnosed with prostate cancer from 1992 to 2007. Of those, 1,181 (0.79%) men received exogenous testosterone following their cancer diagnosis. [/B]We used propensity scoring analysis to examine the effect of testosterone replacement on the use of salvage hormone therapy and overall and prostate cancer-specific mortality. Main Outcome Measures We assessed overall mortality, cancer-specific mortality, and the use of salvage hormone therapy. Results Following prostate cancer diagnosis, testosterone replacement was directly related to income and educational status and inversely related to age (all P < 0.001). Men undergoing radical prostatectomy and men with well-differentiated tumors were more likely to receive testosterone (all P < 0.001). On adjusted analysis, testosterone replacement therapy was not associated with overall or cancer-specific mortality or with the use of salvage hormone therapy. [B]Conclusions In this population-based observational study of testosterone replacement therapy in men with a history of prostate cancer, treatment was not associated with increased overall or cancer-specific mortality. These findings suggest testosterone replacement therapy may be considered in men with a history of prostate cancer, but confirmatory prospective studies are needed.[/B] [B][URL='http://onlinelibrary.wiley.com/doi/10.1111/jsm.12429/abstract']Source[/URL][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Testosterone Replacement Therapy in Men with History of Prostate Cancer Found Safe
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top